H.C. Wainwright Downgrades Aviragen Therapeutics (AVIR) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to H.C. Wainwright Downgrades Aviragen Therapeutics (AVIR) to Neutral

Ladenburg Thalmann Downgrades Aviragen (AVIR) to Neutral

February 14, 2017 8:30 AM EST

Ladenburg Thalmann downgraded Aviragen (NASDAQ: AVIR) from Buy to Neutral.

For an analyst ratings summary and ratings history on Aviragen click here. For more ratings news on Aviragen click here.

Shares of Aviragen closed at $1.08 yesterday.

... More

Aviragen Therapeutics' (AVIR) Phase 2b SPIRITUS Trial of Vapendavir Fails

February 13, 2017 4:02 PM EST

Aviragen Therapeutics (NASDAQ: AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection. Vapendavir did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 (ACQ-6) at day 14, the primary endpoint, for either the 264 mg or 528 mg cohorts compared to placebo.

We are disappointed that the... More